申请人:——
公开号:US20040152629A1
公开(公告)日:2004-08-05
The present invention relates to stilbene and quinone compounds related to combretastatin A-4 and their use as anticancer compounds and prodrugs. The compounds include those with an alkyl group on the double bond of cis or trans-stilbenes, compounds with one or more (and preferably 2 or 3) alkyl group substituents on the stilbene A ring, compounds with an alkoxy group other than methoxy at position 3, 4, and/or 5 of the stilbene A ring, compounds (or prodrugs) in which BOC amino acid esters are formed with the phenolic hydroxyl at the 3-position of the B ring and compounds (or prodrugs) based on a benzoquinone B ring. The present invention further relates to the photochemical reactions of stilbene compounds, either the above compounds disclosed for the first time herein or compounds based on prior art stilbenes. These reactions include the photochemical release of an active form of the compound from a prodrug conjugate and the photochemical isomerisation of the compounds, especially from a trans to cis form of compounds. The reactions can be used alone or in combination to convert inactive or comparatively less active forms of the compounds to more active forms, thereby allowing the compounds to be selectively targeted, e.g. activating them at the site of a tumour.
本发明涉及与康柏他定A-4相关的stilbene和quinone化合物及其作为抗癌化合物和前药的用途。这些化合物包括那些在顺式或反式stilbenes的双键上带有烷基的化合物,带有一个或多个(最好是2个或3个)烷基基团取代物的stilbene A环上的化合物,stilbene A环的3、4和/或5位置带有非甲氧基的烷氧基的化合物,以及在B环的3位的酚羟基形成BOC氨基酸酯的化合物(或前药)和基于苯醌B环的化合物(或前药)。本发明还涉及stilbene化合物的光化学反应,无论是本文首次披露的上述化合物还是基于先前技术的stilbenes的化合物。这些反应包括从前药共轭物中光化学释放出化合物的活性形式以及化合物的光化学异构化反应,特别是从顺式到反式形式的化合物。这些反应可以单独或组合使用,将化合物的非活性或相对不活性形式转化为更活跃的形式,从而使化合物能够被选择性地靶向,例如在肿瘤部位激活它们。